Results 131 to 140 of about 30,028 (235)
Lp(a) levels in Greek patients with heterozygous familial hypercholesterolemia
, 1996 We undertook the present study to evaluate the lipid profile in 82 (51 male, 31 female) Greek individuals with heterozygous familial hypercholesterolemia (FH), aged 13-61 years from 22 families.
Elisaf, M. S. +2 more
core
Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient
, 2017 Familial hypercholesterolemia (FH) is most commonly caused by mutations in the LDL receptor (LDLR), which is responsible for hepatic clearance of LDL from the blood circulation.
Abduljaleel, Zainularifeen +7 more
core +1 more source
Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies
, 2016 Heterozygous familial hypercholesterolemia (HeFH) is characterized by a prevalence of 1/200 (higher than 1/500 as previously estimated): based on this updated prevalence, in Italy there are about 250-300 000 subjects with HeFH.
ZAMBON, ALBERTO
core +1 more source
Uncovering a Windsock Aneurysm of the Interventricular Septum: An Incidental Structural Abnormality
Methodist DeBakey Cardiovascular JournalWe present a case of a 75-year-old female with a history of idiopathic small fiber neuropathy, essential hypertension, and heterozygous familial hypercholesterolemia who was evaluated for exertional dyspnea and fatigue.
Saliha Erdem, Kazim Baser
doaj +1 more source
Early left ventricular abnormalities in children with heterozygous familial hypercholesterolemia
, 2012 Background. There are few data available on cardiac morphology and function in children with heterozygous familial hypercholesterolemia (FH). Such patients represent a unique clinical model to assess the effect of pure hypercholesterolemia on cardiac ...
D'andrea A. +23 more
core +1 more source
Simvastatin (mk 733) in Heterozygous Familial Hypercholesterolemia - a 2-year Trial
, 1989 Simvastatin (MK 733), a new competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, given in daily doses of 20 mg and 40 mg for 104 weeks, has been shown to lower the serum total cholesterol and low density lipoprotein cholesterol level
Harvengt, C., Leclercq, V.
core
Risk of brain infarction in familial hypercholesterolemia.
, 1988 We followed 54 subjects with heterozygous familial hypercholesterolemia for an average of 10 (range 3-14) years. Half were treated surgically with partial ileal bypass and the other half (matched for age, sex, coronary heart disease, blood pressure ...
M Kaste, P Koivisto
core +1 more source
, 1996 A study was conducted to determine the clinical efficacy and tolerability of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase in seven patients with heterozygous familial hypercholesterolemia (FH) (defined as primary ...
00019960 +16 more
core +1 more source
Compound Heterozygous Familial Hypercholesterolemia Detected by Cascade Screening
This report outlines the case of a 13-year-old non-Hispanic White male diagnosed with compound heterozygous Familial Hypercholesterolemia (FH) with a biallelic mutation in the LDLR gene.
Hamilton, Luke +2 more
core
Familial hypercholesterolemia [PDF]
, 2006 Familial hypercholesterolemia is a hereditary disease characterized with the increase of LDL- cholesterol level in plasma as a result of mutational defect of LDL receptor gene. The disease presents in two forms as homozygous and heterozygous.
Güzelmansur, İsmail +3 more
core